Business Wire

Lipella Pharmaceuticals Initiates Its Phase-2a Clinical Trial of LP-10 for Hemorrhagic Cystitis

PITTSBURGH--(BUSINESS WIRE)--Lipella Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on improving cancer survivorship, today announced it has begun recruiting patients in the ...
Seeking Alpha

Lipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial; Announces Late-Breaking Presentation at the Annual Meeting of the American Urological Association

PITTSBURGH, March 16, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (LIPO) (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company") today announced the successful completion of a Phase 2A ...
Healio

Cell therapy effective, safe for BK virus-associated hemorrhagic cystitis after HSCT

Please provide your email address to receive an email when new articles are posted on . BK virus-specific cytotoxic T lymphocytes from healthy donors appeared safe and effective for patients with BK ...
Business Wire

FDA Grants Orphan Drug Designation (ODD) to AlloVir’s Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug ...
ascopubs.org

Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation

BK virus-associated hemorrhagic cystitis (BKV-HC) is a common complication of allogenic hematopoietic stem cell transplantation (AHSCT), particularly in recipients of alternative donor transplants, ...
Nasdaq

Lipella Pharma Announces Top Line Results In Phase 2A Trial Of LP-10 For Hemorrhagic Cystitis

(RTTNews) - Biotechnology company Lipella Pharmaceuticals Inc. (LIPO) announced top line results for its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug ...
Healio

FDA grants orphan drug designation to posoleucel for virus-associated hemorrhagic cystitis

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA granted orphan drug designation ...
Monthly Prescribing Reference

Posoleucel Gets Orphan Drug Status for Virus-Associated Hemorrhagic Cystitis

Posoleucel is being investigated for the treatment and prevention of serious diseases caused by 6 viral pathogens. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ...
Benzinga.com

1MTNB : What's Going On With Matinas Biopharma Holdings Stock?

Matinas Biopharma Holdings, Inc. (AMEX:MTNB) shares are trading higher on Wednesday after the company announced complete clinical resolution of a patient's recurrent hemorrhagic cystitis following ...
Seeking Alpha

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

PITTSBURGH, April 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (LIPO) (Nasdaq: “LIPO”) (“Lipella,” “our,” “us” or the “Company”), a ...
Nasdaq

FDA Grants Orphan Drug Designation (ODD) to AlloVir’s Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated ...

Phase 3 registrational study of posoleucel in virus-associated hemorrhagic cystitis is ongoing An inflammatory disease of the bladder, virus-associated HC is a serious complication of hematopoietic ...